비소세포 폐암환자에서 Gefitinib 투여 중 발생한 급성호흡부전

저자 등은 gefitinib 투약 중 발생한 급성호흡곤란으로 사망한 2 예를 경험하였기에 이를 보고하는 바이다. Gefitinib is an oral selective inhibitor that targets the tyrosine kinase of the epidermal growth factor receptor. The prevalence of interstitial lung disease is 2% in Japan and 0.3% in the USA with a mortality rate of up to one third. W...

Full description

Saved in:
Bibliographic Details
Published inTuberculosis and respiratory diseases Vol. 62; no. 2; pp. 144 - 148
Main Authors 류정선, Jeong Seon Ryu, 김루시아, Lucia Kim, 김철현, Chul Hyun Kim, 김현정, Hyun Jung Kim, 조재화, Jae Hwa Cho, 곽승민, Seung Min Kwak, 이홍렬, Hong Lyeol Lee
Format Journal Article
LanguageKorean
Published 대한결핵 및 호흡기학회 28.02.2007
Subjects
Adverse effect
Gefitinib
Lung cancer
Gefitinib
Adverse effect
Lung cancer
Online AccessGet full text
ISSN1738-3536
2005-6184

Cover

More Information
Summary:저자 등은 gefitinib 투약 중 발생한 급성호흡곤란으로 사망한 2 예를 경험하였기에 이를 보고하는 바이다. Gefitinib is an oral selective inhibitor that targets the tyrosine kinase of the epidermal growth factor receptor. The prevalence of interstitial lung disease is 2% in Japan and 0.3% in the USA with a mortality rate of up to one third. We describe two non-small cell lung cancer patients who developed acute respiratory failure after gefitinib, and suggest that clinicians take extreme caution when deciding to treat patients with gefitinib. (Tuberc Respir Dis 2007; 62: 144-148)
Bibliography:The Korean Academy of Tuberculosis and Respiratory Diseases
KISTI1.1003/JNL.JAKO200730360543012
ISSN:1738-3536
2005-6184